This product is used to control and prevent symptoms (wheezing and shortness of breath) caused by asthma. It contains 2 medications: fluticasone and salmeterol. Fluticasone belongs to a class of drugs ...
On Wednesday, GSK Plc (NYSE:GSK) announced it will cap out-of-pocket costs for eligible patients at no more than $35 per month for all its asthma and chronic obstructive pulmonary disease (COPD) ...
Add Yahoo as a preferred source to see more of our stories on Google. Illustration shows GSK (GlaxoSmithKline) logo (Reuters) -British pharmaceutical giant GSK said on Wednesday it would cap ...
Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Good afternoon! Inhalers will soon get a whole lot cheaper for some Americans. Three of the world's ...
Four U.S. senators, led by Bernie Sanders, I-Vt., have sent letters to the four largest inhaler manufacturers – AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline (GSK) and Teva Pharmaceuticals – ...
A switch in Medicaid's formula could mean many children will go without inhalers in the coming months. The process change means drugmakers have to pay Medicaid if list prices on older products are ...
Several U.S. lawmakers including Sen. Bernie Sanders (I-Vt.) are investigating the prices charged by four large drug companies for their asthma inhalers, arguing the devices unfairly cost Americans ...
AstraZeneca is capping out-of-pocket costs for inhalers and related medication at no more than $35 per month, the drugmaker announced Monday. The pharma giant said the expanded savings are intended to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results